Table 2 Clinical demographic comparisons between mCNVs based on the presence of neovascular signal around PSV
Parameter | Presence of neovascular signal around PSV (n = 20) | Absence of neovascular signal around PSV (n = 31) | P value |
|---|---|---|---|
Age (years) | 51.35 ± 14.35 | 55.52 ± 13.76 | 0.304c |
Gender (n, %) | 0.949a | ||
Female | 15 (75.0%) | 23 (74.2%) | |
Male | 5 (25.0%) | 8 (25.8%) | |
Refractive error (D) | − 12.41 ± 3.41 | − 12.49 ± 2.97 | 0.928c |
Baseline BCVA (logMAR) | 0.75 (0.43–1.30) | 0.52 (0.40–1.00) | 0.137b |
Anti-VEGF (n, %) | 0.557a | ||
Ranibizumab | 12 (60.0%) | 16 (51.6%) | |
Conbercept | 8 (40.0%) | 15 (48.4%) | |
Number of initial injections | 2 (1–3) | 2 (1–3) | 0.784b |
Number of total injections | 3 (2–4) | 2 (2–3) | 0.198b |
Follow- up duration (months) | 30.5 (22–45.5) | 26 (18–38) | 0.284b |
CNV location (n, %) | 0.066a | ||
Subfoveal | 16 (80.0%) | 17 (54.8%) | |
Parafoveal | 4 (20.0%) | 14 (45.2%) | |
CNV area (mm2) | 0.659 (0.178–1.150) | 0.310 (0.180–0.670) | 0.109b |
CNV flow area (mm2) | 0.538 (0.129–0.791) | 0.255 (0.136–0.574) | 0.177b |
CNV pattern (n, %) | 0.133a | ||
“Medusa”: “Seafan”: “Indistinct network” | 10:5:5 | 13:3:16 | |
(50.0%:25.0%:25.0%) | (38.7%:9.7%:51.6%) | ||
Lacquer cracks (n, %) | 7 (35.0%) | 9 (29.0%) | 0.654a |
Posterior staphyloma (n, %) | 17 (85.0%) | 28 (90.3%) | 0.668a |
Retinoschisis (n, %) | 7 (35.0%) | 7 (22.6%) | 0.332a |
Dilated choroidal vein (n, %) | 10 (50.0%) | 7 (22.6%) | 0.043a |
Hyperreflective area height (µm) | 249.50 (185.25–318.50) | 197.00 (150.00–268.00) | 0.080b |
Central foveal thickness (µm) | 304.50 (247.25–405.75) | 263.00 (206.00–378.00) | 0.364b |
Subfoveal choroidal thickness (µm) | 53.00 (24.25–82.25) | 54.00 (36.00–68.00) | 0.847b |